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Abstract In this article we review the ever increasing role
of imaging in endometrial and cervical cancer. Magnetic
resonance imaging (MRI) has emerged as the most widely
used technique in the management of women with
gynaecological cancer. In endometrial cancer, MRI is
reliable in identifying myometrial and cervical invasion
and extra-uterine disease, thereby informing preoperative
surgical planning. In cervical cancer, MRI plays a crucial
role in distinguishing early from advanced disease, thereby
stratifying patients for surgery and chemoradiation. MRI is
also valuable in assessing proximal extension of cervical
tumours in young women with early stage disease for
feasibility of fertility preserving surgery. In both cancers,
imaging is used for diagnosing nodal metastases, detection
of recurrence, and dealing with complications of both the
disease and treatment.
Keywords Endometrial cancer.Cervical cancer.MRI.
FIGO staging.Lymph nodes
Introduction
Although both cervical and endometrial cancers arise in the
uterus, the tumours have quite different aetiologies and
clinical features. Diagnosis is initially made at histology in
both cancers. Imaging is an important adjuvant to clinical
and surgical evaluation. Transvaginal ultrasound (TVUS)
for endometrial cancer, computed tomography (CT),
magnetic resonance imaging (MRI), and
18F-fluorodeoxyglu-
cose positron emission tomography (FDG-PET) have a
significant impact in the management of patients with
endometrial and cervical cancer. The role of imaging
includes tumour staging, treatment planning, assessing
treatment response, and detecting treatment complications
and recurrent disease. For imaging to be used effectively,
however, it is important for the radiologist to understand not
only the treatment options with which the multidisciplinary
team and the patient are faced but also the diagnostic
performance, advantages and limitations of each of these
imaging modalities.
The most widely used staging classification is that of the
International Federation of Gynaecology and Obstetrics
(FIGO). In this article, we review the recent changes to the
FIGO staging classification and discuss the increasing
reliance on imaging in the management of patients with
endometrial and cervical cancer with a particular emphasis
on the role of MRI in primary staging and detecting disease
recurrence.
Endometrial cancer
Carcinoma of the endometrium is the most prevalent
gynaecological malignancy in Western Europe and North
America and its incidence is climbing due to increased life
expectancy and rises in obesity [1, 2]. Endometrial
carcinoma primarily presents in the 6th-7th decades, with
only very few women diagnosed under the age of 35 [3].
Despite being a relatively common malignancy, it is not a
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DOI 10.1007/s13244-010-0042-7leading cause of cancer death, with a 10-year survival rate
of 75%, partly because 75-80% of women present at an
early stage with postmenopausal bleeding [3].
Several recognised risk factors are associated with
endometrial cancer. Any condition which results in pro-
longed unopposed oestrogen stimulation of the endometrial
lining can predispose to endometrial neoplasia. Oestrogen
excess can be exogenous (unopposed oestrogen therapy) or
endogenous, such as in patients with ovarian malfunction,
those with oestrogen secreting tumours or in obese patients
[4]. Long-term use of tamoxifen citrate and nulliparity are
also associated with increased risk [5, 6].
Following presentation, TVUS is widely accepted as the
initial imaging modality. Careful assessment of endometrial
thickness, with an abnormal threshold of 5 mm or greater,
provides a sensitivity of higher than 95% [7]. If the
endometrium is thickened or bleeding continues, sampling
of the endometrial lining is undertaken. Histopathological
diagnosis and tumour grade can either be obtained as an
outpatient, using a pipelle biopsy sampling technique, or by
hysteroscopic assessment with dilatation and curettage in
theatre.
A recent study by Todo et al. [8], which reviewed 671
patients with endometrial carcinoma, more than 90% were
found to have adenocarcinomas. Of these, 52% were Grade
1 tumours (well differentiated), 25% were Grade 2 tumours
(moderately differentiated) and 15% were Grade 3 (undif-
ferentiated) carcinomas. The remaining 8% were associated
with a poorer prognosis and included clear cell carcinoma
and serous adenocarcinoma [8]. The prognosis of endome-
trial carcinoma depends on the age of the patient,
histological tumour grade, cell type, tumour stage and
lymph-node status [9, 10]. New data from the study by
Todo and co-workers supports these findings where the
presence of para-aortic nodal metastasis has the most
impact on prognosis (hazard ratio of 3.07 compared with
a hazard ratio of 1.81 for age over 56 years and a hazard
ratio of 1.87 for Grade 3 or non-endometriod histology) [8].
Table 1 [11] summarises the risk factors for pelvic and
para-aortic lymph-node metastases which depend on the
depth of myometrial and cervical invasion, tumour grade
and tumour occupying more than one-third of the endome-
trial cavity. The depth of myometrial and cervical stromal
invasion are therefore key prognostic factors due to an
association with nodal metastases. Creasman et al. [10]
demonstrated in Grade 3 tumours that there was a 9%
incidence of nodal metastases if only superficial myome-
trial invasion was present (involving the inner third), but
this figure increased to 34% when deep myometrial
invasion was present (involving the outer third). The depth
of myometrial invasion is also a strong prognostic factor
regarding the 5-year survival rate. In patients with no
myometrial invasion and low-grade histology, the 5-year
survival rate is 95%, compared with 42% in patients with
tumour invasion extending into the outer half of the
myometrium and high grade histology [1].
Staging and treatment
Clinical staging of endometrial carcinoma is inaccurate
and often underestimates the extent of disease [12]. As a
result, FIGO staging of endometrial cancer was reclassi-
fied in 1988 as a surgico-pathological staging system [13]
and was again revised in 2009 (Table 2)[ 14, 15].
Therefore full FIGO staging requires a total abdominal
hysterectomy (TAH), bilateral salpingo-ophrectomy (BSO),
peritoneal washings, assessment and sampling of pelvic
and para-aortic lymph-nodes. This surgico-pathological
staging system is independent of radiological staging or
assessment.
Conventional treatment of endometrial cancer performed
in most patients is TAH and BSO with peritoneal washings
and this is the current FIGO staging method for full staging
of the tumour. Lymphadenectomy remains a component of
the surgical-pathological staging of endometrial cancer.
However, as recently stated by Dowdy et al. [16], ‘the lack
of consensus for primary surgical treatment for endometrial
cancer, the most common gynaecological malignancy, is
deplorable’. The disadvantage of lymphadenectomy is that
it carries a significant complication rate of 17-19%, requires
increased anaesthetic and operating times and needs the
expertise of a specialised oncologic surgeon [17, 18]. The
rate of pelvic lymph node involvement in Stage I
endometrial cancer (i.e. confined to the corpus) is low at
approximately 10% [19]. Although nodal metastases have
been dectected in up to 29% of patients in intermediate to
high risk categories in a recent series [8]. Patient selection
for primary lymphadenectomy at the time of hysterectomy
is, therefore, presently controversial in oncological gynae-
cology. In some centres, the majority of patients undergo
surgical lymphadenectomy [8]. Conversely, lymphadenec-
tomy is not widely practiced in the UK and is variable in
the US, where there is a much lower rate of lymphadenec-
tomy by gynaecologists (26%) and specialist gynaecologic
oncologists (83%) [20, 21].
In many centres, surgical planning is dependent upon
prognostic risk factors. Patients at low risk of extra-
uterine spread (Grade 1 or 2 histology, new FIGO Stage
<1B) may be treated with TAH and BSO alone. In these
cases, formal lymphadenectomy is not always performed,
however any suspicious appearing nodes on imaging or
at surgery will be resected. This policy is supported by
findings of two recently published trials. A randomised
clinical trial assessing lymphadenectomy versus no lympha-
denectomy in Stage I endometrial carcinoma demonstrated no
improvement in disease free or overall survival following
310 Insights Imaging (2010) 1:309–328lymphadenectomy [22]. Similarly, the ASTEC trial demon-
strated no benefit in overall survival or recurrence-free
survival with pelvic lymphadenectomy in women with Stage
I endometrial cancer [19]. In patients with high risk disease
(Grade >2, new FIGO Stage >1A), full surgical staging,
including lymphadenectomy is recommended. The validity
of these trial results has been questioned in view of relatively
short duration of follow-up and limited extent of lymphade-
nectomy (nine or fewer nodes were removed in 35% of
patients).
A large retrospective study from Japan has challenged
the findings presented by Kitchener et al. [19]a n d
Benedetti et al. [8, 22]. Toda et al. [8] reported a significant
improvement in overall, disease-specific and recurrence-
free survival in patients with intermediate or high risk
disease who undergo complete pelvic and para-aortic nodal
dissection compared with pelvic dissection alone. Despite
these published findings, there is still a range of practice
concerning resection of lymph nodes and this procedure
remains part of the formal staging of disease.
Controversy still surrounds the use of adjuvant therapy
in endometrial carcinoma and there is no consensus [23].
Studies have shown in patients with low or intermediate
risk disease that external beam radiotherapy (EBRT) can
reduce the risk of pelvic relapse, but it has no impact on
overall survival [24]. However, EBRT is associated with a
10% survival advantage in patients with high risk disease
[25]. Vaginal brachytherapy (VBT) is associated with
reduced toxic effects and a recently published randomised
trial has demonstrated that VBT is as effective as EBRT for
the prevention of vaginal recurrence following surgery in
high- to intermediate-risk patients and therefore should
become the standard of care [26] Chemotherapy can be
used in patients with aggressive histological subtypes,
Table 2 FIGO staging of endometrial carcinoma and corresponding MR findings (revised 2009)
FIGO
Stage
Description MRI findings
Stage I
a Tumour confined to the corpus uteri
IA Tumour extending to <50% of myometrial depth Signal intensity of tumour extends into <50% of myometrium.
Partial or full thickness disruption of the junctional zone
IB Tumour extending to >50% of myometrial depth Signal intensity of tumour extends into >50% of myometrium.
Full thickness disruption of the junctional zone
Stage II
a Tumour invades cervical stroma, but does not extend
beyond the Uterus
Internal os and endo-cervical canal are widened.
Disruption of low signal stroma
Stage III
a Local and/or regional spread of the tumour
IIIA Tumour invades the serosa of the corpus uteri and/or
adenexae
Disruption of continuity of outer myometrium. Irregular uterine
configuration
IIIB Vaginal and/or parametrial involvement Segmental loss of hypointense vaginal wall
IIIC Metastases to pelvic and/or para-aortic lymph nodes Regional or para-aortic nodes >1 cm in short axis diameter
IIIC1 Positive pelvic nodes
IIIC2 Positive para-aortic lymph nodes ± positive pelvic lymph
nodes
Stage IV
a Tumour invades bladder and/or bowel mucosa, and/or
distant metastases
IVA Tumour invasion of bladder and/or bowel mucosa Tumour nodules protruding in the bladder/rectal lumen
IVB Distant metastases, including intra-abdominal metastases
and/or inguinal lymph nodes
Tumour in distant sites or organs
aPositive cytology obtained at peritoneal washings should be recorded but does not alter any stage
Risk Group Features
High Any age and all three features listed below:
1. Grade 3 adenocarcinoma
2. >50% deep myometrial invasion
3. Lymphovascular space invasion
Intermediate >50 years and any two of the above features
>70 years and any one of the above features
Low Grade 1 and 2 adenocarcinoma and no or superficial myometrial invasion
Table 1 Risk groups for pelvic
and para-aortic nodal disease
in endometrial cancer
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palliative measure [23].
Imaging
The ability to select patients for lymphadenectomy prior to
surgery may, therefore, be of value. Imaging can assist in
preoperative assessment and surgical planning by predict-
ing the depth of myometrial invasion, cervical stromal
involvement, distant spread and lymph-node involvement.
Preoperative knowledge of these factors is important, as
patients with disease greater than FIGO Stage 1A may
benefit from lymphadenectomy, but the number of unnec-
essary lymph-node dissections can also be reduced in low
risk patients by showing that none of these factors are
present [27].
Histological diagnosis before staging is essential, as
imaging cannot accurately differentiate endometrial carci-
noma from polyps or hyperplasia [28].
TVUS has been used to evaluate the depth of myometrial
and cervical invasion, but this is operator-dependant and,
thus, the reported accuracies vary between 77-91% [29]. As
there is relatively little contrast difference between tumour
and myometrium, CT is not sensitive or specific enough to
assess the depth of myometrial or cervical involvement. For
detection of deep myometrial invasion, the sensitivity and
specificity are 83% and 42%, respectively [30], with an
overall staging accuracy of between 58-76% [31]. CT
performs as well as MRI in identifying extrauterine spread
and identifying nodal metastases [32].
MRI is considered the most accurate imaging modality
for preoperative assessment of endometrial carcinoma due
to its excellent soft-tissue contrast resolution. Overall
accuracies have been reported at 83-92% [33, 34]. MRI is
probably of greatest value in evaluating tumours that may
be at risk of extrauterine spread, where a tumour mass is
seen at ultrasound and histology is Grade 2 or 3. The MRI
findings corresponding to the FIGO Stage of endometrial
cancer are summarised in Table 2.
MRI technique and tumour appearance
Patients are asked to fast for 4-6 h and antiperistaltic agents
may be used to limit peristaltic artefact from the bowel [35].
High-resolution T2-weighted images are obtained in the
sagittal plane and oblique axial plane (small field of view),
perpendicular to the endometrial cavity, to enable assess-
ment of depth of myometrial and cervical invasion.
Following injection of contrast medium, fat-saturated T1-
weighted images, ideally in the sagittal and axial oblique
plane, have been shown to significantly improve pretest
probability of myometrial invasion in all grades of
adenocarcinoma [36]. Dynamic post-contrast T1-weighted
images are also helpful in distinguishing between the
enhancement of tumour, subendometrial mucosal layer
and myometrium. Optimal tumour to myometrial contrast
usually occurs at 50–120 s after injection of contrast
medium, with myometrium enhancing more than the
invading tumour [36]. Wide field-of-view images of the
upper abdomen are obtained to look for para-aortic lymph
nodes, metastases and any complications, such as hydro-
nephrosis [37].
The normal zonal uterine anatomy is clearly delineated
on T2-weighted imaging, where the normal endometrium is
of high signal intensity, with a low signal intensity
junctional zone and intermediate signal intensity of the
myometrium. Endometrial carcinoma is usually isointense
to the myometrium on T1-weighted sequences and of lower
signal intensity than the endometrial lining on the T2-
weighted sequences. On T1-weighted post-contrast images,
the tumour typically enhances less than normal myome-
trium, and on dynamic contrast enhancement enhances
more slowly than myometrium.
Pitfalls in staging of endometrial carcinoma on MRI
include blood in the endometrial cavity due to recent
dilatation and curettage or tumour haemorrhage, extreme
thinning of the myometrium, poor natural contrast between
the tumour and myometrium, adenomyosis and leiomyo-
mata [11, 38].
Preoperative staging on MRI
The criteria used in FIGO staging system may be applied to
preoperative MRI. Stage 0 has been removed recently from
the FIGO staging classification [14].
Stage I
Stage I tumours are confined to the uterine corpus,
comprising over 80% of cases. In Stage IA disease, there
is typically focal or diffuse thickening of the endometrium
by tissue that has lower signal intensity than normal
endometrium. Myometrial invasion (of less than 50% for
Stage IA) may be diagnosed when the intermediate signal
of the tumour is seen breeching the junctional zone and
extending into the myometrium on T2-weighted and post-
contrast images (Figs. 1 and 2). Subtle irregularity may be
seen between the margin of the tumour and the junctional
zone in cases of early invasion. In cases where the
junctional zone is not visible or indistinct, a smooth
interface between the endometrium and myometrium is
considered to represent an intact myometrium.
When the tumour disrupts the junctional zone and is
seen to extend more than 50% into the deep myometrium, it
is classed as Stage IB disease (Fig. 3); however, an outer
stripe of normal myometrial tissue remains intact [28, 39].
312 Insights Imaging (2010) 1:309–328The degree of invasion should be assessed on both T2-
weighted images in the sagittal and oblique axial views as
well as post-contrast images.
Stage II
Stage II disease is direct invasion of the cervical stroma
(Figs. 4 and 5). Identification is important as 50–67% of
patients with cervical stromal invasion have lymph-node
involvement or other sites of extrauterine disease [40, 41].
Normal cervical stroma is hypointense on T2-weighted
imaging and endometrial carcinoma is intermediate to
hyperintense. The assessment of cervical involvement may
be improved on late dynamic post-contrast T1-weighted
imaging, which can help distinguish between true invasion
and a protruding polypoid tumour into the endocervical
canal [42]. In Stage II disease, tumour extends into and
widens the endocervical canal and internal os with
disruption of the fibrocervical stroma. The overall accuracy
of MRI in predicting cervical involvement is reported as
90-92%, with sensitivities of 75-80% and specificities of
94-96% [43–45].
Stage III
Stage III is disease outside the uterus but not beyond the
true pelvis. In Stage IIIA disease, invasion of the uterine
serosa or adnexae is identified (Fig. 6). On the T2-weighted
images, tumour may be seen to extend beyond the outer
margin of the uterus and, on the contrast-enhanced T1-
weighted images, there is loss of the normal rim of brightly
enhancing myometrium. Tumour deposits in the ovaries,
even in the absence of serosal invasion may also be
identified. In the revised FIGO staging, positive peritoneal
cytology from peritoneal washings alone does not consti-
tute Stage IIIA disease.
In Stage IIIB disease, there is tumour involvement of the
vagina or parametria, either by direct extension or as
Fig. 1a, b Endometrial cancer
FIGO 1A. a Sagittal and b
oblique axial T2-weighted MRI.
There is intermediate T2 signal
intensity soft tissue within the
endometrium (arrows). No
breach of the junctional zone is
visible and the interface between
the tumour and junctional zone
is well defined
Fig. 2a, b Endometrial cancer
FIGO IA. a Sagittal T2-
weighted and b para-sagittal
post-contrast images. There is a
large volume of tumour within
the endometrial cavity. There is
invasion of the myometrium,
extending to <50% of the myo-
metrial thickness (arrow). The
post-contrast image demon-
strates the typical bright en-
hancement of the myometrium
with intermediate enhancement
of the tumour
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signal intensity tumour invading through the low signal
intensity vaginal wall is seen.
Regional nodal involvement indicates Stage IIIC disease;
IIIC1 indicates involvement of pelvic nodes (Fig. 7),
whereas Stage IIIC2 indicates positive para-aortic nodes,
with or without pelvic nodal involvement. Lymph-nodes
are hypointense on T1-weighted images and intermediate
intensity on T2-weighted imaging [46]. Nodal metastases
correspond to drainage sites of involved portions of the
uterus. The middle and lower aspects drain to the para-
metrium, paracervical and obturator nodes. The upper
corpus and fundus drain to common iliac and para-aortic
lymph-nodes. The diagnosis of nodal involvement on CT
and MRI uses size criteria with a cut off of 1 cm minimum
axial diameter. This results in a low sensitivity for detection
of lymph-node metastases and diagnosis on MRI remains
unsatisfactory [44, 46].
Stage IV
Directinfiltrationofthebladderorbowelmucosa is StageIVA
disease(Fig.8). This is seen as loss of the low signal intensity
wall of the bladder or rectum on T2-weighted images and
tumour nodules in the mucosa of the invaded organ [42]. In
Stage IVB disease, there are distant metastatic deposits or
peritoneal deposits with or without inguinal lymph-node
involvement. Peritoneal deposits may be outlined by ascites
and are best seen on delayed contrast-enhanced images, but
deposits of less than 1 cm may be difficult to identify on any
imaging modality [42]. Distant spread to lung, liver and
bones is rare at presentation and usually occurs haematoge-
nously, the lung being the most common site involved.
FDG-PET/CT
The primary role for FDG-PET/CT is for detection of
extrauterine disease. A study comparing MRI with FDG-
PET/CT demonstrated no statistically significant difference in
the detection of lymph-node metastases in patients with
endometrial carcinoma [47]. There was a high negative
predictive value for nodal involvement (94-96%) on both
imaging modalities. FGD-PET/CT did, however, detect
distant metastatic disease with a sensitivity of 100% and a
specificity of 94% [24, 47]. FDG-PET/CT is not generally
considered sensitive enough to replace lymph-node dissection.
Recurrent disease
Endometrial carcinoma has a low rate of recurrence of 4-16%
[8, 24]. Factors that predict relapse include advanced stage at
presentation, high-grade histology, age over 60 years and
Fig. 4 Endometrial cancer Stage II. Sagittal T2-weighted image
demonstrates tumour in the endometrial cavity (black arrow) which
extends into the endocervical canal and invades the upper cervical
stroma (white arrow) at the internal os
Fig. 3a, b Endometrial cancer
FIGO IB. a The tumour (arrow)
is poorly defined on the T2-
weighted image, in this case.
Depth of myometrial invasion is
difficult to assess. b Dynamic
post contrast image clearly
defines the brightly enhancing
myometrium from the tumour.
The depth of myometrial inva-
sion is greater than 50%
(arrows)
314 Insights Imaging (2010) 1:309–328lymphovascualar invasion [24]. Following primary surgery,
64% of recurrences occur within 2 years and 87% within 3
years, the commonest sites being lymph nodes and vaginal
vault (Fig. 9)[ 48]. Less frequently, it may manifest as
peritoneal carcinomatosis (Fig. 10), or distant metastases in
liver, lung or bones. Routine follow-up has a poor yield in
detecting recurrence in the asymptomatic patient, but
identification of those patients with an increased risk of
recurrence and the likely time scale could direct an
appropriate strategy for follow-up imaging.
Fig. 5a, b Endometrial cancer
extending into the endocervical
canal. a Sagittal and b oblique
axial T2-weighted images dem-
onstrate an intermediate signal
intensity mass (black arrow).
This lesion was thought to be
confined to the endocervical
canal but on histology there was
minimal invasion of tumour into
the cervical stroma (FIGO II). In
retrospect, there is some thin-
ning of the low signal intensity
cervical stroma (white arrow).
Minimal invasion of the stroma
is difficult to report confidently
and remains a potential pitfall
Fig. 6a–d Endometrial cancer
Stage IIIA. a Sagittal and b
para-sagittal T2-weighted
images demonstrate the tumour
within the endometrial cavity
(white arrow). To the left of
midline, there is a tumour de-
posit lying along the peritoneal
reflection between the uterus
and bladder (black arrow). c
Oblique axial T2-weighted im-
age demonstrates the peritoneal
mass (black arrow) as well as a
mass in the right ovary (white
ovary). d Axial T1-weighted
image following administration
of gadolinium demonstrates en-
hancement of the right ovarian
deposit
Insights Imaging (2010) 1:309–328 315CT performs well in the detection of recurrent pelvic and
distantdisease,withanoverallaccuracyof92%[49]. MRI has
also been advocated for this indication to evaluate surgical
resectability. FDG-PET/CT has been shown to be helpful in
the assessment of patients with suspected recurrence [50]. In
one study, FDG-PET/CT detected unsuspected distant me-
tastases in nine out of 26 patients which significantly altered
the treatment choices [50]. A recently published study
compared PET integrated with low-dose non-enhanced CT
to PET integrated with contrast-enhanced CT [51]. It
concluded that PET with contrast-enhanced CT is an accurate
imaging modality for the assessment of uterine cancer
recurrence and the use of contrast reduces the frequency of
equivocal interpretations [51].
Cervical cancer
Cervix cancer remains one of the commonest cancers in
women in developing countries, including Central and South
America, parts of Africa, and South Central Asia [3]. During
the last several decades, cervical cancer incidence and
mortality rates have declined substantially in Western
countries with the introduction of screening programmes,
which detect pre-invasive disease on cervical smears [52].
However, the survival rates for patients who present with
invasive cervical cancer have not improved over the same
period. Younger women tend to present with earlier stages of
the disease, with older women being diagnosed with later
stages of the disease.
The most important aetiological factor is exposure to human
papilloma virus (HPV), types 16 and 18. The introduction of
the vaccine against HPV 16 and 18 is likely to have a major
impact on disease prevention [53]. Other risk factors include
smoking, lower socio-economic class and the oral contracep-
tive pill. The commonest histological type is squamous cell
carcinoma, which accounts for approximately two thirds of all
cases and arises at the external os. Adenocarcinoma and
adenosquamous carcinomas account for 10-25% of cases [3].
Most patients with invasive cervical cancer are asymptomatic
at its early phase, and patients with advanced disease typically
present with abnormal vaginal bleeding.
Fig. 7a, b Endometrial cancer
FIGO IIIC1. a Sagittal T2-
weighted image demonstrates a
tumour within the endometrial
cavity (black arrow), which
extends into the endocervical
canal and invades the cervical
stroma (white arrow). b Oblique
axial T2-weighted images dem-
onstrates an enlarged right ex-
ternal iliac lymph node (arrow)
Fig. 8a, b Endometrial cancer
FIGO IVA. a Sagittal and b
oblique axial T2-weighted
images demonstrate a large tu-
mour replacing and distorting
the uterus. There is breach of the
uterine serosa and invasion of
the adjacent sigmoid colon
(black arrow) and pelvic side-
wall (white arrow)
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The classic staging of cervical cancer uses the FIGO
classification. The FIGO staging system has undergone a
number of revisions over the past few decades, most recently
in 2009 [14, 54]( T a b l e3). Unlike the staging of other
gynaecological cancers, the FIGO staging of cervical cancer
is entirely clinical and does not rely on surgico-pathological
findings. This is mainly to achieve a staging system that is
universally available and as cervical cancer is more prevalent
in developing countries, only clinical methods are universally
available. The staging procedure includes examination of the
cervix under anaesthesia, colposcopy, biopsy, cystoscopy and
sigmoidoscopy, although the last two are optional [14, 54].
Conventional radiographic techniques included are chest
X-ray,bariumenemaandintravenousurography.Intherevised
FIGO staging, incorporation of cross-sectional imaging (CT
and MRI) is encouraged where available [14, 54].
Clinical staging is inherently inaccurate in evaluating
several important staging parameters, including assessment
of parametrial and pelvic sidewall invasion, accurate
measurement of tumour size (particularly in endocervical
or infiltrating tumours), and evaluation of lymph node
metastases. Clinical staging errors occur in up to 25% of
Stage I and Stage II disease; in 50-65% of Stage IIA to IIIB
disease; and in 67% of Stage IVA disease [55, 56]. Overall,
compared with surgery, clinical staging underestimates the
stage in 25-67% of cases and overestimates in 2% [55].
Accurate pre-treatment evaluation is not only important for
prognosis but also for determining appropriate mode of
treatment. The key decision in determining the patients
management is whether or not the disease extends into the
parametrium. In general, extension into the parametrium
excludes primary surgery. However with greater targeting of
conformal radiotherapy and the efficacy of chemoradiation
larger tumours are increasingly being treated primarily with
chemoradiation even without parametrial extension.
Tumour staging on MRI
Over the past several years, the role of MRI in gynaecological
oncology has evolved. Owing to its superior soft tissue
delineation, MRI is now the most widely used imaging
modality in initial staging of primary cervical cancer. It is
important in monitoring response and detecting recurrence,
demonstrating complications of the disease itself and of
treatment, determining feasibility of uterus-preserving sur-
gery, and planning radiotherapy. Furthermore, it has also been
demonstrated to be cost-effective by limiting or eliminating
theneedforfurtherdiagnostictestsorsurgicalprocedures[57,
58].
The FIGO staging system can be readily applied to MRI
appearances (Table 3).
Stage I
Stage IA (microinvasive) tumours usually show no visible
disease on T2-weigthed images. The shape of the cervix
maybe distorted due to diagnostic cone biopsy. Stage IB
tumours appear as hyperintense or intermediate signal
intensity mass relative to the low signal intensity of the
cervical stroma on T2-weighted images. In young patients,
in whom the cervix may have an intermediate signal
intensity, delineation of the tumour can be challenging.
Tumour of 4 cm or less is staged as IB1 (Fig. 11) and
tumour greater than 4 cm is IB2 (Fig. 12). Size is an
important determinant of patient management, as many
Fig. 10 Recurrent endometrial cancer. Sagittal T2-weighted image
demonstrates serosal recurrence at the rectosigmoid colon (arrow)
Fig. 9 Recurrent endometrial cancer. Sagittal T2-weighted image
demonstrates a intermediate T2 signal intensity recurrent mass at the
vaginal vault (arrow)
Insights Imaging (2010) 1:309–328 317centres offer chemoradiation for bulky tumours in place of
surgery, despite an absence of parametrial spread.
Clinical examination is poor at estimating tumour size,
especially when the tumour primarily occurs in the
endocervix. MRI has been shown to be highly accurate in
the assessement of tumour size, within 5 mm of the surgical
size in 70-90% of cases [59], with an overall accuracy of
93% [60]. In a recent retrospective study of 150 surgically
Table 3 FIGO clinical staging of cervical carcinoma and corresponding MRI findings (Revised 2009)
FIGO Stage Description MRI findings
I Tumour confined to cervix
IA Microscopic invasive tumour No evidence of tumour
IA1 Stromal invasion ≤3 mm, width ≤7m m
IA2 Stromal invasion >3 mm but ≤5 mm, width ≤7m m
IB Clinically visible invasive tumour or pre-clinical tumours
greater than Stage IA
Intermediate SI mass against low SI of the background
cervical stroma
IB1 Tumour ≤4c m
IB2 Tumour >4 cm
II Invasion beyond uterus but not to pelvic side wall or
lower third of vagina
IIA No parametrial invasion, upper two-thirds of vagina Loss of the normal low SI of the vaginal fornix or wall, usually
contiguous with the primary cervical tumour mass
IIA1 Tumour ≤4c m
IIA2 Tumour >4 cm
IIB Parametrial invasion Breach of the low SI ring of the cervical stroma
III Tumour extends to pelvic sidewall and/or involves the
lowest third of vagina
IIIA Tumour extends to lower third of vagina, not to
pelvic sidewall
Loss of the normal low SI of the vaginal wall in the
lower third of vagina
IIIB Extension to pelvic sidewall and/or hydronephrosis or
non-functioning kidney
Presence of tumour within 3 mm of internal obturator, levator ani
and pyriformis muscles or the iliac vessels. Additional signs are
increased SI and/or retraction of pelvic muscles, presence of
hydronephrosis due to ureteral obstruction at the level of the
primary tumour
IV Tumour extends outside true pelvis or invades
bladder or rectal mucosa
IVA Invasion of bladder or rectal mucosa Tumour nodules protruding into the bladder/rectal lumen.
IVB Distant metastasis Tumour involving organs outside the true pelvis, includes the
para-aortic and inguinal nodes
SI signal intensity
Fig. 11a, b Endophytic cervical
cancer Stage IB1. a Sagittal T2-
weighted image demonstrates an
intermediate signal intensity
mass within the endocervical
canal (arrow). b Oblique axial
T2-weighted image perpendicu-
lar to endocervical canal dem-
onstrates tumour surrounded by
an intact ring of cervical stroma
(arrow)
318 Insights Imaging (2010) 1:309–328staged patients carried out in our own institution, the mean
difference in tumour size between MRI and histology was –
0.9 mm, with 95% limits of agreement between -12.6 to
+13 mm. In tumours greater than 10 mm, mean difference
was 0.3 mm and limits of agreement were -7.5 to +7.9 mm
[61]. This has important implications for delineation of the
gross tumour volume for radiotherapy and for assessing the
feasibility of uterus-preserving surgery.
Stage II
In Stage IIA, tumour infiltrates the upper two-thirds of the
vagina without parametrial invasion. On MRI there is
thickening and loss of the normal low signal intensity
vaginal wall, in contiguity with the tumour mass (Fig. 13).
A common source of confusion are large exophytic tumours
that distend the vagina and are misinterpreted to represent
vaginal involvement. Compared with clinical examination,
MRI is highly sensitive (86-93%) in the depiction of
vaginal infiltration [60]. FIGO now divides Stage II into
IIA and IIB as the prognosis of large primary tumours
(>4 cm) and vaginal infiltration has a worse prognosis than
if the primary tumour is less than 4 cm.
Parametrial invasion indicates Stage IIB disease. The
radiological sign for parametrial invasion is breach of the low
signal intensity ring of cervical stroma, best demonstrated on
oblique axial high resolution images (Fig. 14). Additional
features include a spiculated tumour-parametrium interface,
soft tissue extension into the parametria and along the cardinal
or uterosacral ligaments, encasement of the periuterine
vessels; and in some cases the cervix may be pulled over to
the side with parametrial invasion [62].
A common pitfall is the presence of a bulky exophytic
tumour arising from the vaginal portion of the cervix. In
this situation, disruption of the cervical stromal ring does
not necessarily indicate parametrial invasion because the
tumour may still be separated from the parametrium by the
vaginal fornix (Fig. 12).
The accuracy for detection of parametrial invasion on
MRI ranges from 88 to 97%, sensitivity ranges 44-100%,
and specificity 80-97% [59, 61, 63–66]. Preservation of the
low signal intensity ring virtually excludes parametrial
invasion with a negative predictive value of 94-100% [61,
62, 64]. However, the positive predictive value of disrup-
tion of the stromal ring is lower (82-86%) [67, 68] as it can
be difficult to differentiate peritumoural oedema from
parametrial invasion, particularly in large tumours. It is
the ability to rule out parametrial invasion on MRI with a
high negative predictive value, which is of greatest value
clinically as it confidently identifies patients suitable for
radical surgery.
Fig. 13 Cervical cancer Stage IIA2. Sagittal T2-weighted image
showing a ‘barrel-shaped’ cervical tumour (T) that extends into the
upper anterior vagina (white arrow). The normal posterior vagina has
a low signal intensity (black arrow)
Fig. 12a, b Exophytic cervical
cancer Stage IB2. a Sagittal T2-
weighted image showing a
exophytic tumour (T) greater
than 4 cm arising from the
posterior lip of the cervix. b
Oblique axial T2-weighted
image showing that although
the tumour has breeched the
cervical stromal ring (asterisk)
it is still surrounded by the
vaginal wall (arrows)
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In Stage IIIA, tumour extends down to the lower third of
the vaginal wall (Fig. 15). When tumour extends to the
pelvic sidewall or causes hydronephrosis, it is classified as
Stage IIIB (Fig. 16). Pelvic sidewall involvement is defined
as tumour within 3 mm of the obturator internus, levator
ani, and pyriformis muscles or the iliac vessels [69].
Stage IV
In Stage IVA, the tumour invades the bladder (Fig. 17)o r
rectal mucosa (Fig. 18). Due to the relative ‘bare area’ of
bladder posteriorly below the level of the peritoneal
reflection, bladder invasion is more common than infiltration
of the rectal wall as a deep peritoneal reflection and
rectovaginal septum are interposed. Rectal invasion usually
occurs via the uterosacral ligaments [70]. Contiguous
extension of tumour from the cervix to the wall of the
bladder or rectum, with loss of the intervening fat plane, may
indicate serosal involvement. Focal or diffuse disruption of
the normal low signal intensity muscle wall, resulting in a
nodular or irregular appearance, suggests muscle invasion of
the bladder or rectum. Mucosal invasion is seen as overt
masses protruding into the lumen. Bullous oedema of the
bladder is indicative of a nonspecific mucosal reaction to
impaired perfusion, and raises the suspicion of bladder wall
invasion but is not diagnostic of mucosal invasion.
The reported sensitivity of MRI in the evaluation of
bladder or rectal invasion is 71-100%, and the specificity is
88-91% [58, 60, 71]. If a low threshold for reporting
bladder and rectal invasion is adopted, MRI has been
shown to have a very high negative predictive value of
100% [58], thereby negating the need for invasive
cystoscopic or endoscopic staging.
Fig. 16 Cervical cancer Stage IIIB. Oblique axial T2-weighted image
demonstratestumourinvadingtheparametriumbilaterally(white arrows)
and the left ureter (black arrow) causing ureteral obstruction
Fig. 15 Cervical cancer Stage IIIA. Sagittal T2-weighted image
showing a cervical tumour (T) that extends into the lower third of the
vagina (arrow). The division between the upper and lower two-thirds
of the vagina is approximately at the level of insertion of the urethra
into the bladder base (asterisk)
Fig. 14a, b Barrel-shaped
cervical cancer Stage IIB. a
Sagittal T2-weighted image
demonstrate a large tumour (T)
which diffusely infiltrates the
whole cervix circumferentially.
b Oblique axial T2-weighted
image demonstrates disruption
of the low signal cervical stroma
ring (short arrow) and shows
the tumour extending into the
right parametrium (long arrow)
320 Insights Imaging (2010) 1:309–328Stage IVB indicates distant metastatic disease outside the
true pelvis. Although pelvic node metastases do not change
the FIGO Stage, para-aortic or inguinal metastases are
classified as Stage IVB (Fig. 19) and indicate a poorer
prognosis.
Performance of MRI and CT
The overall staging accuracy of MRI ranges from 77 to
90% [59, 60, 63, 71–73]. In single institution studies, MRI
performs better than CT in the depiction of parametrial
invasion and overall staging accuracy [57, 71, 72, 74]. A
systematic review of 57 single institution studies also
showed that MRI was more accurate than CT for overall
staging of cervical cancer [71]. The sensitivity of MRI in
detecting parametrial invasion was 74% compared with
55% for CT, and for bladder and rectal invasion the
sensitivities were 75% and 71% respectively, higher
compared with CT [71]. The prospective multi-centre study
undertaken by the American College of Radiology Imaging
Network (ACRIN) and the Gynecologic Oncology Group
(GOG) compared MRI and CT in the patients with early
invasive cervical cancer. As the probability of extra-cervical
disease was low, the study showed that contrast enhanced
multi-detector CT was equivalent to MRI for overall
preoperative staging. However, MRI performed significantly
better for visualisation of the primary tumour and
detection of parametrial invasion. In addition, CT has
much greater inter-observer variability when compared
with MRI [75]. MRI, therefore, has great advantages in
assessing the feasibility for trachelectomy or for planning
modern conformal radiotherapy.
Importance of proximal extension
Young women with early Stage I disease who wish to
preserve fertility can be offered fertility preserving surgery
or trachelectomy. In this procedure, the tumour-bearing
cervix is removed and the uterine body is re-anastomsed to
the vagina with insertion of a cerclage suture to maintain
isthmic competency during pregnancy [76]. An important
criterion for surgery is that the proximal end of the tumour
should be 1 cm or more distal to the internal os to permit
tumour-free re-anastomosis. This cannot be reliably deter-
mined clinically by the examining gynaecologist, and MRI
has been shown to be a reliable method of predicting
involvement of the internal os by tumour, with a sensitivity
Fig. 17 Cervical cancer Stage IVAwith bladder invasion. Sagittal T2-
weighted image demonstrates a large tumour (T) in the cervix which
invades the full width of the posterior bladder wall
Fig. 18a, b Cervical cancer
Stage IVA with rectal invasion.
a Sagittal and b oblique axial
T2-weighted images demon-
strate a large tumour (white
arrow) which extends through
the fat plane between the cervix
and rectum. The rectum and
mesorectum are extensively
involved (black arrows)
Insights Imaging (2010) 1:309–328 321of 100% and specificity of 96% [77], making MRI essential
when considering trachelectomy.
Proximal extension of tumour is also an important
feature in predicting prognosis in patients with higher stage
disease. In a study of 70 patients by Narayan et al. [78], the
presence of proximal extension beyond the internal os and
myometrial invasion as seen on MRI increased the
probability of nodal metastases to 75% versus 11% in
patients without proximal extension. Nodal metastases were
considered to be involved with tumour if they demonstrated
positive tracer uptake on FDG-PET scans. The presence of
nodal metastases had a significant negative association with
disease-specific and disease-free survival [78].
Nodal metastases
Within the pelvis, cervical cancer spreads first to para-
metrial nodes, then to obturator, internal and external iliac
nodes. In more advanced disease, common iliac and para-
aortic nodes may be involved. In a recent 25-centre
ACRIN/GOG study, lymphatic metastases were found in
55 of 161 women (34%) with early invasive cervical
cancer, verified by lymphadenectomy. Of these 55 women,
62% had metastases restricted to the low pelvis (defined as
not involving the common iliac or above); 13% had
common iliac metastases; and 9% had para-aortic metasta-
ses [79]. Although not incorporated in the FIGO staging
system, presence of lymph node metastases has significant
prognostic and treatment consequences. The 5-year survival
for node positive patients is 39-54% compared with 67-
92% in patients without nodal involvement [80, 81]. In
early stage tumour, involvement of any node is important as
it excludes curative surgery changing the treatment to either
chemoradiotherapy alone, or debulking surgery and neo-
adjuvant chemoradiotherapy. In higher stage tumours,
detection of para-aortic nodes is important for planning
the extent of the radiation field.
On cross-sectional imaging, size is the main criterion
used to diagnose nodal metastasis and the most widely
quoted threshold above which a node is considered
malignant is 10 mm in short-axis diameter. Other features
of malignancy include a round shape (for nodes with a short
axis diameter of between 8 and 10 mm) [82], central
necrosis, soft tissue of the same signal intensity of the
tumour within the node and extracapsular extension of
tumour beyond the nodal capsule [83]. The presence of
visible necrosis within the node, seen as pockets of high T2
signal intensity, has a positive predictive value of 100% for
nodal involvement [84]. Conversely, a long thin shape and
a fatty hilum are in favour of a benign node, even though
enlarged.
MRI and CT have comparable overall accuracies in
detecting nodal metastases [84]. Using standard size
criteria, sensitivities on MRI are low, ranging from 29 to
86% [46, 59, 66, 85]. CT and MRI are unable to detect
micrometastases in normal-sized nodes, and to differentiate
reactive enlargement from malignant infiltration. The
performance of MRI is greatly improved by use of
lymph-node-specific MRI contrast agents, such as ultra-
small superparamagnetic iron oxide particles (USPIOs).
These are intravenously administered to the patient at the
time of the staging MRI. The contrast agent is transported
via the interstitial space to lymph nodes, where they are
taken up by normal macrophages. The presence of USPIOs
within normal, macrophage-laden nodes results in loss of
signal on T2-weighted sequences. In lymph nodes replaced
by tumour deposits there is no loss of signal. The use of
USPIOs improves the sensitivity of MRI (using standard
size criteria of nodes) from 29% to 82-93%, whilst
maintaining a high specificity at 97% [46].
Studies into the diagnostic performance of FDG-PET/CT
show varying results depending on the stage of the primary
tumour. FDG-PET/CT has a sensitivity of 75-100% and
specificity of 87-100% in advanced disease (FIGO IIB to
IVB) [67, 86–88]. In these patients FDG-PET also
improves initial staging by demonstrating unexpected
disease beyond the pelvis or retroperitoneum, such as
supraclavicular nodal metastases [89], altering management
Fig. 19a, b Cervical cancer
Stage IVB. a Axial oblique
T2-weighted image showing a
cervical tumour (T) extending
into the parametrium (white
arrows), uterosacral ligament
(asterisk) and posterior bladder
wall (black arrow). b Axial
contrast-enhanced CT in the
same patient, showing an
enlarged left para-aortic lymph
node (arrow)
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value of FDG-PET in early-stage disease (FIGO I to IIA) is
questionable. Many studies have reported low sensitivities
for the detection of nodal metastases, ranging from 25-73%
[91–94]. Chao et al. [90] concluded that PET/CT has a
limited role in staging for patients with early-stage disease
and should not replace lymphadenectomy for the detection
of lymph node metastases. Overall, FDG-PET/CT is
increasingly incorporated into cervical cancer management
and a strong correlation has been found between pretreat-
ment FDG-PET/CT lymph node status and patient disease-
free survival [95].
Recurrent disease
Cervical cancer recurrence is defined as local tumour
regrowth or development of distant metastases at least
6 months after the primary lesion has regressed. Residual
disease is that which is evident within 6 months of primary
treatment. Approximately 30% of women with cervical
cancer die of residual or recurrent disease after primary
treatment [96]. Sixty percent of recurrences occur within
the first 2 years following initial treatment, and 90% by
5 years [97]. The identification of recurrent disease is
important, as salvage treatment has a 5-year survival rate of
46-52% compared with 5% in untreated disease [98]. The
majority of recurrences occur in the central pelvis. A
retrospective study in our own centre, evaluated MRI
appearances of recurrent cervical cancer in 49 patients, of
whom 70.4% recurred within 1 year following treatment. In
patients receiving radiotherapy, 67% of recurrences were in
the cervix, whilst 87% of post-surgical recurrences were in
the vaginal vault. Only 13% of patients had recurrent
disease outside the pelvis without evidence of pelvic
disease [99].
Just as primary staging dictates initial management,
location of recurrent disease, initial therapy and clinical
condition of the patient will determine subsequent treat-
ment. Local recurrent disease in the vaginal cuff (Fig. 20)
or pelvic side walls (Fig. 21) after surgery may be treated
with chemoradiotherapy. In patients who have already
received chemoradiotherapy, central recurrence limited to
the cervix and/or vagina may be treated with exenteration.
Pelvic exenteration is reserved for young women with low
co-morbidity and a central pelvic recurrence without
peritoneal disease, vessel encasement, involvement of the
pelvic sidewall or nodal metastases [100]. In the past CT
was invaluable in predicting the feasibility of exenteration,
but this has now been superceded by PET/CT. Distant
metastatic disease may be treated with chemotherapy.
Due to its inherent contrast resolution MRI is superior in
distinguishing radiation fibrosis from active disease and is
of greater value than CT in identifying recurrent disease.
On MRI, recurrent disease appears as a mass of interme-
diate to high signal intensity on T2-weighted sequences;
established radiotherapy fibrosis usually is of low signal
intensity on T2-weighted sequences. However, differentia-
tion can be difficult particularly in the first 6 months after
radiotherapy when areas of high signal intensity may exist
due to inflammation and oedema. Where morphological
imaging is suboptimal in this differentiation, we have found
that functional imaging aids diagnosis. These include
dynamic contrast-enhanced MRI, diffusion weighted imag-
ing and FDG-PET/CT.
Fig. 21 Recurrent cervical cancer. Axial oblique T2-weighted image
demonstrating a recurrent right pelvic side-wall mass (arrow). This
encases the external iliac artery and vein and extends to the bony
cortex. This would not be suitable for pelvic exenteration
Fig. 20 Recurrent cervical cancer. Sagittal T2-weighted image
showing a recurrent mass at the vaginal vault (arrow). This patient
had localised central recurrence only and would therefore be suitable
for pelvic exenteration
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intensity-time curves has been shown to improve the ability
of MRI to detect tumour recurrence following radiotherapy.
In a study by Kinkel et al. [101], comparing dynamic
contrast-enhanced MRI with standard T2-weighted sequen-
ces, specificity and accuracy increased from 22% and 68%
to 67% and 83% respectively. The optimal time to
demonstrate tumour enhancement was between 45 and 90
s[ 101]. In patients with suspected recurrence clinically,
FDG-PET/CT has been reported to be accurate in confirm-
ing the presence or absence of recurrent disease with
sensitivities of 90.3−92.7% and specificities of 81−100%
[102, 103]. This is a higher sensitivity than CT and MRI
alone for detecting recurrent disease.
The delineation of fistulae
MRI is preferable to CT in patients undergoing radiother-
apy treatment to distinguish complications and effects of
treatment from recurrent disease. Fistulae can occur as a
result of primary or recurrent tumour or as consequence of
surgery or radiotherapy and result in significant morbidity
[104]. Vaginal fistulas are typically either vesicovaginal or
enterovaginal, and are the most common type of fistula in
patients with cervical cancer [105]. The appearance of a
fistula on MRI depends on whether it is filled with fluid,
air, or a combination of the two. On T2-weighted images, a
fistula is typically seen as a high signal intensity fluid-filled
communication (Fig. 22). An air-filled tract produces low
signal intensity on MRI. The sagittal plane is preferred for
the detection of vaginal fistulas as it allows optimal
depiction of disruption of the posterior bladder wall in a
vesicovaginal fistula and discontinuity of the posterior
vaginal or anterior rectal wall in a rectovaginal fistula.
In a prospective study performed at our institution, 15
patients with clinical symptoms suggestive of a vaginal
fistula were evaluated. MRI correctly indentified nine of the
ten fistulae confirmed at surgery [106] and correctly
differentiated between fistulae secondary to recurrence and
those secondary to radiotherapy effects. Based on our
results, we concluded that MRI is accurate in demonstrating
the course, extent and complexity of vaginal fistulae, and in
revealing associated active or recurrent disease.
Fig. 23 Post-trachelectomy appearance. Sagittal T2-weighted image
following fertility preserving surgery for early stage cervical cancer.
The cervix has been removed with a cuff of vaginal fornix and
parametrium. The lower uterine segment has been anastomsed onto
the upper vagina (white arrow). Soft tissue posterior to the
anastomosis is normal vaginal wall and represents a ‘neo-fornix’
(black arrow)
Fig. 22 Cervical cancer and rectovaginal fistulation. Sagittal T2-
weighted image demonstrates a large tumour which replaces the entire
cervix and extends into the myometrium and upto the internal os.
There is a fistula between the vagina and the anterior rectum
containing fluid and air (arrow)
Fig. 24 Recurrent cervical cancer. Sagittal T2-weighted image
showing a recurrent mass (arrow) at the utero-vaginal anastomosis
in a patient who has had a previous trachelectomy
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MRI is routinely used for surveillance to detect early
recurrence in women who have undergone trachelectomy
[107]. Recurrence rates following trachelectomy are low,
with a figure of 4% quoted [108]. It is important to be
aware of normal MRI postoperative appearances and to be
able to discriminate between normal appearances (Fig. 23)
and recurrent disease (Fig. 24) to avoid misinterpretation. In
work carried out in our institution, three important
appearances were observed after trachelectomy that should
be recognised as normal and not recurrent disease [107]. In
56% of patients, there was a posterior ‘puckering’ of the
vaginal wall, which the authors termed a ‘neo-fornix’
(Fig. 23). In 6%, diffuse thickening of the vaginal wall
was present up to 1 year after surgery and slowly resolved
without treatment. Thirdly, 4% of patients had slowly
resolving haematomas in the vaginal wall. Suture artefacts
also occur from uterovaginal anastomotic cerclage sutures
used during the procedure. To date, these have not limited
the diagnostic ability of MRI. Pelvic lymphocoeles and
concurrent benign disease (endometriosis and adenomyo-
sis) were also common findings.
Planning radiotherapy
Over the past few decades, advances in radiotherapy
equipment have resulted in high-precision radiotherapy
techniques, such as conformal and intensity-modulated
radiotherapy (IMRT). The increased conformality of mod-
ern radiotherapy design necessitates improved means of
delineating the tumour (gross tumour volume) for treat-
ment. CT is the current standard imaging modality for
radiotherapy planning but has inferior soft tissue contrast to
MRI. The gross tumour volume on CT has been shown to
be substantially larger than that measured on MRI [75]. It is
crucial, therefore, that CT is correlated with MRI when
defining the gross tumour volume. The co-registration of
MRI and CT images with radiotherapy planning systems is
the subject of ongoing research.
Conclusion
Imaging has assumed increasing importance in the man-
agement of patients with gynaecological cancer in recent
years. This trend reflects a desire to obtain accurate staging
and early disease detection to provide optimal treatment
and minimise morbidity and mortality. MRI, although not
officially incorporated in the FIGO staging system, is
widely accepted as the most reliable imaging modality for
staging and follow-up. In endometrial cancer, MRI is
accurate in assessing the depth of myometrial extension
and cervical extension, allowing for selective lymph node
sampling or lymphadenectomy. In cervical cancer, MRI is
important in local staging and in assessing proximal
extension of tumours in young women for feasibility of
fertility preserving surgery. In summary, the role of MRI is
now well established, and future protocols may also
incorporate functional imaging techniques that integrate
both morphological and biological information which offer
promise as early indicators of treatment response.
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